Form 4: RxSight Executive Exercises Options and Sells Shares Under 10b5-1 Plan

An RxSight executive, Ilya Goldshleger, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Ilya Goldshleger, a Co-President and Chief Operating Officer at RxSight, Inc., executed transactions involving the company's stock.
• On November 22, 2024, and November 26, 2024, Goldshleger exercised stock options to acquire 3,100 shares of common stock on each day at a price of $15.08 per share.
• On the same days, Goldshleger sold 3,100 shares of common stock at $45.00 and $45.88 per share respectively.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on June 3, 2024.
• Following these transactions, Goldshleger directly owns 42,246 shares of common stock and indirectly owns 1,372 shares through a spouse.

Sentiment

Score: 5

Explanation: The document reflects routine transactions under a pre-arranged plan, indicating a neutral sentiment.

Industry Context

This is a routine filing related to executive stock transactions and is common for publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the medical device industry like RxSight.
• Similar filings are regularly seen from executives at companies such as Alcon (ALC) and Johnson & Johnson (JNJ), which also have significant stock-based compensation programs.
• The vesting schedule of the options, with 1/48th vesting monthly, is a typical structure for equity grants.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-arranged trading plan.
• The transactions do not impact employees, customers, suppliers or creditors.

Key Dates

Keywords

stock options, Rule 10b5-1, insider trading, stock sale, executive compensation, RxSight, RXST